Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech develops clinical-stage natural killer cell therapeutics, with news centered on troculeucel, its patient-specific, ex vivo expanded autologous NK cell immunotherapy candidate also known as SNK01. Company updates commonly address Alzheimer’s disease, frontotemporal dementia and cancer development, including conference presentations, clinical and biomarker analyses, mechanistic data and regulatory naming for the program.
Recurring disclosures also cover NKGen’s OTC quotation and trading status, capital-market communications, scientific advisory activity and its majority-owned Korean affiliate, NKGen Biotech Korea Co., Ltd., which develops NK cell therapies and commercializes bioreagents and immunodiagnostic technologies.
NKGen Biotech (OTC:NKGN) activated three new U.S. clinical trial sites for its ongoing Phase 2 trial of troculeucel in moderate Alzheimer’s disease. New locations in New Jersey, New York, and Florida broaden geographic reach, improving access for patients and physicians and potentially supporting enrollment across multiple regions.
NKGen Biotech (OTC:NKGN) will present mechanistic and early clinical data for lead candidate troculeucel at the 8th Annual Neuroimmunology Drug Development Summit, April 14-16, 2026.
The presentation on April 16, 2026 at 11:00 AM ET will describe selective targeting of autoreactive T cells, biomarker trends, and reductions in cerebrospinal fluid neuroinflammatory signals.
NKGen Biotech (OTC: NKGN) reported pooled Phase 1 troculeucel data presented at AD/PD 2026 showing dose‑responsive cognitive improvements and biomarker correlations in Alzheimer’s disease. In moderate AD patients (n=6) 100% were stable or improved at three months and 50% improved from moderate to mild on CDR‑SB.
Exploratory plasma GFAP correlated with clinical measures (r up to 0.76, p≤0.009) and higher doses (4–6B cells) showed stronger associations; two patients had maintained benefit through 12 months. No treatment‑related adverse events were reported.
NKGen Biotech (OTC: NKGN) will present integrated Phase 1 clinical and biomarker analyses for troculeucel in Alzheimer’s disease at AD/PD 2026 (March 17–21, 2026) in Copenhagen and virtually. Presentations include an oral symposium talk on March 21 and a poster on March 20–21 examining cognition and plasma GFAP associations. The analyses combine patient-level data from two completed Phase 1 trials to assess dose-response on cognitive measures and GFAP biomarker correlations. These data do not include the company’s ongoing Phase 2 trial results.
NKGen Biotech (OTC: NKGN) appointed Bruce L. Miller, M.D. to its Scientific Advisory Board on January 22, 2026. Dr. Miller is a leading expert in Alzheimer’s disease, frontotemporal dementia (FTD), and neurocognitive disorders and directs the Edward and Pearl Fein Memory and Aging Center at UCSF.
The company said Dr. Miller will advise clinical and scientific priorities as NKGen advances its Phase 2 trial of autologous NK cell therapy troculeucel in moderate Alzheimer’s disease and explore troculeucel use in FTD after early expanded-access signals.
NKGen Biotech (OTC: NKGN) announced board changes at its majority-owned Korean affiliate NKGen Korea following a shareholder-approved name change on November 21, 2025. NKGen Korea disclosed KOSDAQ appointments of Hanhan Xu, Xuan Zhang, and Dr. June H. Lee to three-year terms, and earlier appointed Dr. Angie You on August 14, 2025 to a one-year term. Leadership backgrounds span scientific development, operations, finance, and venture roles across Asia and the U.S.
The company said it supports the appointments as majority shareholder and expects the new directors to aid NKGen Korea as it emerges from rehabilitation and advances NK cell therapeutic development and commercialization in the Asia-Pacific region.
NKGen Biotech (OTC: NKGN) clarified that recent $0.00 price displays on some financial sites reflect quote dissemination limits on the OTC Expert Market, not the company’s underlying value. Quotations were moved to the OTC Expert Market on or about July 17, 2025 after the company failed to remain current in Exchange Act filings. The company confirmed its common stock remains listed and tradable, but public price quotes and volume are restricted to broker‑dealers and institutions. NKGen filed its Form 10‑K on October 8, 2025 and is working to file Form 10‑Qs for the quarters ended Mar 31, Jun 30, and Sep 30, 2025 to regain compliance and restore public market data access.
NKGen Biotech (OTC:NKGN) will present at the XXVII World Congress of Neurology in Seoul, South Korea on October 12–15, 2025. CEO Paul Y. Song, M.D., will deliver a presentation on troculeucel, an investigational autologous enhanced natural killer (NK) cell therapy for moderate/advanced Alzheimer’s disease.
The talk, titled "Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Moderate/Advanced Alzheimer’s Disease. Scientific Rationale with Preliminary Clinical and Biomarker Results," is scheduled for October 15, 2025 at 11:50 AM KST in Conference Room North 201 during the Free Paper – Ataxia and Cerebellar Disorders & Dementia session. A copy of the presentation will be posted under the company’s Scientific Publications page after the event.
NKGen Biotech (OTC: NKGN), a clinical-stage biotech company, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou on September 25-26, 2025. CEO Paul Y. Song will discuss their investigational NK cell therapy, troculeucel, for neurodegenerative diseases.
The presentation will take place at the Sino-Singapore Guangzhou Knowledge City International Convention Center on September 25, 2025, at 3:20 PM CST. The forum will host over 1,200 experts and 90 speakers, focusing on cell and gene therapy, RNA therapeutics, and stem cell research.
NKGen Biotech (OTC: NKGN) has successfully completed the acquisition of a 65% controlling stake in NKMax Co., Ltd. for $16.9 million. The strategic transaction, funded by AlpineBrook Capital GP 1 Limited and CEO Dr. Paul Y. Song, transforms NKGen into a fully integrated cell therapy company with complete control over global manufacturing infrastructure and intellectual property assets.
The acquisition marks a significant turnaround for NKGen, which faced challenges after NKMax's bankruptcy in 2024 and its own delisting from Nasdaq. The deal secures NKMax's operations through 2026 and positions NKGen to advance its lead therapeutic candidate, troculeucel, which has received FDA fast track designation and shown promising results in over 90% of Alzheimer's patients treated to date.